Effects of Treatment with a Bone-Targeted Prostaglandin E2 Receptor 4 Agonist C3 (Mes-1007) in a Mouse Model of Severe Osteogenesis Imperfecta.
Sign Up to like & getrecommendations! Published in 2021 at "Bone"
DOI: 10.1016/j.bone.2021.115867
Abstract: OBJECTIVE Osteogenesis imperfecta (OI) is a heritable bone fragility disorder that is usually caused by mutations affecting collagen type I synthesis in osteoblasts. Bisphosphonates are widely used to decrease fracture rate but are only partially… read more here.
Keywords: combination; zoledronate; treatment; mes 1007 ... See more keywords